Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Shah

Showing results (241-250 of 296) with videos related to

Pageof 30
Sort By:
Molecular Nutrition & Food Research|November 6, 2013
Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteersJane F Ferguson, Claire K Mulvey, Parth N Patel, et al.
The American Journal of Gastroenterology|June 12, 2023
Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid TumorsMarcel Yibirin, Khalis Mustafayev, Jeff Hosry, et al.
The Oncologist|June 30, 2026
Divergent Biology and Outcomes of Somatic Transformations in Germ Cell TumorsZachariah Thomas, Andrew C Johns, Michael Glover, et al.
The New England Journal of Medicine|October 24, 2024
CRISPR-Based Therapy for Hereditary AngioedemaDanny M Cohn, Padmalal Gurugama, Markus Magerl, et al.
BJUI Compass|April 27, 2022
Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinomaOmar Alhalabi, Matthew T Campbell, Lianchun Xiao, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 20, 2023
Incidence and Geographical Distribution of Adrenocortical Carcinoma: Retrospective Analysis of a State Cancer RegistryVania Balderrama-Brondani, Allison M Griffin, Taylor J Owen, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2019
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitorsA Y Shah, R R Kotecha, E A Lemke, et al.
Cell Reports|October 19, 2017
UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibitionTeresa Ezponda, Daphné Dupéré-Richer, Christine M Will, et al.
The Lancet. Oncology|June 10, 2022
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trialRobert J Motzer, Thomas Powles, Mauricio Burotto, et al.
Cancer|November 20, 2020
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignanciesBradley Alexander McGregor, Matthew T Campbell, Wanling Xie, et al.
Pageof 30

Showing results (241-250 of 296) with videos related to

Sort By:
Pageof 30
Molecular Nutrition & Food Research|November 6, 2013
Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteersJane F Ferguson, Claire K Mulvey, Parth N Patel, et al.
The American Journal of Gastroenterology|June 12, 2023
Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid TumorsMarcel Yibirin, Khalis Mustafayev, Jeff Hosry, et al.
The Oncologist|June 30, 2026
Divergent Biology and Outcomes of Somatic Transformations in Germ Cell TumorsZachariah Thomas, Andrew C Johns, Michael Glover, et al.
The New England Journal of Medicine|October 24, 2024
CRISPR-Based Therapy for Hereditary AngioedemaDanny M Cohn, Padmalal Gurugama, Markus Magerl, et al.
BJUI Compass|April 27, 2022
Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinomaOmar Alhalabi, Matthew T Campbell, Lianchun Xiao, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 20, 2023
Incidence and Geographical Distribution of Adrenocortical Carcinoma: Retrospective Analysis of a State Cancer RegistryVania Balderrama-Brondani, Allison M Griffin, Taylor J Owen, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2019
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitorsA Y Shah, R R Kotecha, E A Lemke, et al.
Cell Reports|October 19, 2017
UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibitionTeresa Ezponda, Daphné Dupéré-Richer, Christine M Will, et al.
The Lancet. Oncology|June 10, 2022
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trialRobert J Motzer, Thomas Powles, Mauricio Burotto, et al.
Cancer|November 20, 2020
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignanciesBradley Alexander McGregor, Matthew T Campbell, Wanling Xie, et al.
Pageof 30